Kirill Peskov

i.m. sechenov first moscow state medical university

H指数:17

被引数:959

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Bayesian Workflow for Minimal PBPK Models: Case Study of Dapagliflozin

贝叶斯工作流程在最小PBPK模型中的应用：达格列净案例研究

CPT-Pharmacometrics & Systems Pharmacology

IF3

2026-09-150

OAAI

A Systematic Comparative Analysis of Tumor Size Models Based on Erlotinib Clinical Data in Advanced NSCLC

基于厄洛替尼临床数据的晚期NSCLC肿瘤大小模型系统性比较分析

cpt pharmacometrics systems pharmacology

IF0

2025-08-110

OAAI

An Integrative Mechanistic Model of Type 1 IFN-Mediated Inflammation in Systemic Lupus Erythematosus

系统性红斑狼疮中1型IFN介导炎症的整合机制模型

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2025-05-130

Mathematical modeling in autoimmune diseases: from theory to clinical application (vol 15,1371620,2024)

FRONTIERS IN IMMUNOLOGY

IF5.9

2025-01-300

OAAI

Systematic review and quantitative meta-analysis of age-dependent human T-lymphocyte homeostasis

年龄依赖性人类T淋巴细胞稳态的系统评价和定量荟萃分析

FRONTIERS IN IMMUNOLOGY

IF5.9

2025-01-270

OAAI

Addressing Project Optimus: Preclinical, modelling and clinical data to support identification of the Recommended Phase 2 Dose for saruparib

EUROPEAN JOURNAL OF CANCER

IF7.1

2024-10-010

PRE

Mathematical modeling of endogenous and exogenously administered T cell recirculation in mouse and its application to pharmacokinetic studies of cell therapies

FRONTIERS IN IMMUNOLOGY

IF5.9

2024-04-171

OAAI

Mathematical modeling in autoimmune diseases: from theory to clinical application

FRONTIERS IN IMMUNOLOGY

IF5.9

2024-03-140

OAAI

An integrative mechanistic model of thymocyte dynamics

胸腺细胞动力学的综合机制模型

FRONTIERS IN IMMUNOLOGY

IF5.9

2024-02-261

OAAI

A tutorial for model-based evaluation and translation of cardiovascular safety in preclinical trials

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2023-11-230

OAAI

Model-Based Assessment of the Reference Values of CAVI in Healthy Russian Population and Benchmarking With CAVI0

AMERICAN JOURNAL OF HYPERTENSION

IF3.1

2023-09-114

PRE

A Quantitative Systems Pharmacology (QSP) model to characterize dosedependent antitumor activity of AZD5305, PARP1 selective inhibitor, across multiple xenograft models

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance

免疫检查点抑制剂与癌症放射治疗的结合: 打破阻力墙的锤子

FRONTIERS IN ONCOLOGY

IF3.3

2022-12-0523

OAAI

Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19

卡米司他甲磺酸盐对新型冠状病毒肺炎SARS-CoV-2预测疗效的半机制药代动力学-药效学模型

MICROBIOLOGY SPECTRUM

IF3.8

2022-04-274

OAAI

A workflow for the joint modeling of longitudinal and event data in the development of therapeutics: Tools, statistical methods, and diagnostics

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2022-02-218

Applications of Model-Based Meta-Analysis in Drug Development

PHARMACEUTICAL RESEARCH

IF4.3

2022-02-1630

OAAI

Evaluation of Combination Strategies for the A2AR Inhibitor AZD4635 Across Tumor Microenvironment Conditions via a Systems Pharmacology Model

FRONTIERS IN IMMUNOLOGY

IF5.9

2021-03-0212

OAAI

Longitudinal Tumor Size and Neutrophil-to-Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Durvalumab

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2020-12-2119

OAAI

Cycle Network Model of Prostaglandin H Synthase-1

PHARMACEUTICALS

IF4.8

2020-09-233

OAAI

Quantification of Scheduling Impact on Safety and Efficacy Outcomes of Brain Metastasis Radio- and Immuno-Therapies: A Systematic Review and Meta-Analysis

FRONTIERS IN ONCOLOGY

IF3.3

2020-09-028

OAAI

Kirill Peskov

个人简介

教育背景

工作经历

荣誉奖项

研究方向